Skip to main content
. 2019 Jun 25;10(4):1453–1463. doi: 10.1007/s13300-019-0658-7

Fig. 1.

Fig. 1

Efficacy measures a change in HbA1c between baseline and 6 months. b Change in fasting plasma glucose between baseline and 6 months. c Change in body weight between baseline and 6 months. d Percentages of patients achieving the HbA1c targets of < 7.0% or ≤ 6.5% after 6 months of treatment with dulaglutide